VERO Biotech Inc, an Atlanta, Georgia-based company focused on saving lives, alleviating suffering, and improving the health economics of care, today announced that the company was awarded the prestigious Golden Helix "Innovation Award" for its breakthrough development of the GENOSYL® Delivery System, the first advancement in the delivery of inhaled nitric oxide in 20 years, and the "Deal of the Year" Award for 2022 by Georgia Bio, the state's life science trade association.

The Golden Helix Awards celebrate the contributions and achievements of Georgia leaders working to advance the growth of the life sciences industry and foster organizational strategic partnerships that can create a healthier world. This is the 24^th year GA Bio will recognize Golden Helix Award winners showcasing the best in innovation and leadership.

"This year's Golden Helix Award for 'Innovation' and 'Deal of the Year' is a further reflection of the hard work and dedication of VERO employees to alleviate patient suffering from cardio-pulmonary diseases, as well as continued investor confidence in VERO's ability to bring innovative products to market," said Brent V. Furse, CEO and President, VERO Biotech.

GENOSYL® DS is the first and only tankless inhaled nitric oxide (NO) delivery system approved by the U.S. Food and Drug Administration (FDA). NO dilates pulmonary blood vessels and may be used to improve oxygenation in neonates with hypoxic respiratory failure and pulmonary hypertension. Unlike tank-based systems, GENOSYL® DS generates NO at the bedside using a small disposable cassette. This eliminates the need for hospitals to manage large, cumbersome tanks and helps to simplify clinical workflow. GENOSYL® DS is currently available in more than 100 hospital systems nationally.

The Awards will be presented at a formal in-person ceremony on Thursday, May 5, 2022. The event is expected to draw 300 of the state's life sciences industry leaders.